Dasatinib (BMS-354835) Versus Imatinib Mesylate in Subjects With Chronic Myeloid Leukemia
Public ClinicalTrials.gov record NCT00103844. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Randomized Multi-Center Open Label Study of BMS-354825 vs. Imatinib Mesylate (Gleevec) 800 mg/d in Subjects With Chronic Phase Philadelphia Chromosome-Positive Chronic Myeloid Leukemia Who Have Disease That is Resistant to Imatinib at a Dose at 400 - 600 mg/d
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
The primary purpose of this study is to estimate the major cytogenetic response rates of BMS-354825 and imatinib (800 mg/d) in subjects with chronic phase, Philadelphia chromosome positive, chronic myeloid leukemia (PH+ CML) with disease resistant to imatinib at a dose of 400-600 mg/d.
Study identification
- NCT ID
- NCT00103844
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 2
- Enrollment
- 150 participants
Conditions and interventions
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Feb 2005 (Type not available)
- Primary completion
- Aug 2006 (Actual)
- Completion
- Mar 2008 (Actual)
- Last update posted
- Aug 10, 2010
2005 – 2008
United States locations
- U.S. sites
- 53
- U.S. states
- 25
- U.S. cities
- 53
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Local Institution | Birmingham | Alabama | — | — |
| Local Institution | Anaheim | California | — | — |
| Local Institution | Bakersfield | California | — | — |
| Local Institution | Fullerton | California | — | — |
| Local Institution | Loma Linda | California | — | — |
| Local Institution | Los Angeles | California | — | — |
| Local Institution | Monterey Park | California | — | — |
| Local Institution | San Diego | California | — | — |
| Local Institution | Santa Barbara | California | — | — |
| Local Institution | Santa Maria | California | — | — |
| Local Institution | Stanford | California | — | — |
| Local Institution | Vallejo | California | — | — |
| Local Institution | Aurora | Colorado | — | — |
| Local Institution | Hartford | Connecticut | — | — |
| Local Institution | Washington D.C. | District of Columbia | — | — |
| Local Institution | Jacksonville | Florida | — | — |
| Local Institution | Tampa | Florida | — | — |
| Local Institution | Athens | Georgia | — | — |
| Local Institution | Atlanta | Georgia | — | — |
| Local Institution | Lawrenceville | Georgia | — | — |
| Local Institution | Tucker | Georgia | — | — |
| Local Institution | Chicago | Illinois | — | — |
| Local Institution | Peoria | Illinois | — | — |
| Local Institution | Indianapolis | Indiana | — | — |
| Local Institution | Kansas City | Kansas | — | — |
| Local Institution | Lexington | Kentucky | — | — |
| Local Institution | Boston | Massachusetts | — | — |
| Local Institution | Minneapolis | Minnesota | — | — |
| Local Institution | Rochester | Minnesota | — | — |
| Local Institution | Columbia | Missouri | — | — |
| Local Institution | Kansas City | Missouri | — | — |
| Local Institution | St Louis | Missouri | — | — |
| Local Institution | Omaha | Nebraska | — | — |
| Local Institution | Hackensack | New Jersey | — | — |
| Local Institution | Morristown | New Jersey | — | — |
| Local Institution | New Brunswick | New Jersey | — | — |
| Local Institution | Cary | North Carolina | — | — |
| Local Institution | Chapel Hill | North Carolina | — | — |
| Local Institution | Oklahoma City | Oklahoma | — | — |
| Local Institution | Tulsa | Oklahoma | — | — |
| Local Institution | Portland | Oregon | — | — |
| Local Institution | Pittsburgh | Pennsylvania | — | — |
| Local Institution | Greenville | South Carolina | — | — |
| Local Institution | Nashville | Tennessee | — | — |
| Local Institution | Dallas | Texas | — | — |
| Local Institution | Fort Worth | Texas | — | — |
| Local Institution | Houston | Texas | — | — |
| Local Institution | San Antonio | Texas | — | — |
| Local Institution | Tyler | Texas | — | — |
| Local Institution | Norfolk | Virginia | — | — |
| Local Institution | Seattle | Washington | — | — |
| Local Institution | Spokane | Washington | — | — |
| Local Institution | Vancouver | Washington | — | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 78 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT00103844, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Aug 10, 2010 · Synced Oct 31, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT00103844 live on ClinicalTrials.gov.